Skip to content

ASPIRE BIOPHARMA HOLDINGS, INC.: 10-Q filed 2026-08-13

What ASPIRE BIOPHARMA HOLDINGS, INC. reported in its quarterly report filed 2026-08-13 (fiscal Q2 2026): 35 published measures, 98 facts as tagged in accession 0001493152-26-037819.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-13
Fiscal period
fiscal Q2 2026
Accession
0001493152-26-037819 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ASPIRE BIOPHARMA HOLDINGS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-3013,540,544USD
At 2025-12-311,312,166USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-06-301,782,723USD
At 2025-12-317,688,495USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-3011,757,821USD
At 2026-03-313,868,463USD
At 2025-12-31-6,376,329USD
At 2025-06-30-9,616,785USD
At 2025-03-31-7,952,742USD
At 2024-12-31-1,540,088USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-06-3012,167,136USD
At 2025-12-311,003,904USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-1,268,142USD91
2026-01-01 to 2026-06-30-4,491,034USD181
2026-01-01 to 2026-03-31-3,222,892USD90
2025-04-01 to 2025-06-30-1,981,293USD91
2025-01-01 to 2025-06-30-17,922,621USD181
2025-01-01 to 2025-03-31-15,941,328USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-5,154,196USD181
2025-01-01 to 2025-06-30-2,891,838USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2026-04-01 to 2026-06-3063,104USD91
2026-01-01 to 2026-06-3091,457USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-3016,317,428USD181
2025-01-01 to 2025-06-303,094,438USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-31,749,115USD
At 2025-12-31-27,258,081USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,037,874shares91
2026-01-01 to 2026-06-30599,714shares181
2025-04-01 to 2025-06-3041,111shares91
2025-01-01 to 2025-06-3036,410shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,037,874shares91
2026-01-01 to 2026-06-30599,714shares181
2025-04-01 to 2025-06-3041,111shares91
2025-01-01 to 2025-06-3036,410shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-1.22USD/shares91
2026-01-01 to 2026-06-30-7.49USD/shares181
2025-04-01 to 2025-06-30-48.19USD/shares91
2025-01-01 to 2025-06-30-492.24USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-1.22USD/shares91
2026-01-01 to 2026-06-30-7.49USD/shares181
2025-04-01 to 2025-06-30-48.19USD/shares91
2025-01-01 to 2025-06-30-492.24USD/shares181

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-06-30157,500USD181
2025-01-01 to 2025-06-3014,131,250USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-2,678,222USD91
2026-01-01 to 2026-06-30-4,324,391USD181
2025-04-01 to 2025-06-30-799,890USD91
2025-01-01 to 2025-06-30-16,356,370USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-3013,465,544USD
At 2025-12-311,312,166USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2025-01-01 to 2025-06-30817,824USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-301,686,196USD
At 2025-12-317,592,833USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2026-06-30972,108USD
At 2025-12-311,014,377USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-04-01 to 2026-06-302,648,136USD91
2026-01-01 to 2026-06-304,300,055USD181
2025-04-01 to 2025-06-30799,890USD91
2025-01-01 to 2025-06-3016,356,370USD181

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2026-06-30288,450USD
At 2025-12-31253,160USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-30,086USD91
2026-01-01 to 2026-06-30-24,336USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-30233,482USD91
2026-01-01 to 2026-06-30530,205USD181
2025-04-01 to 2025-06-30352,887USD91
2025-01-01 to 2025-06-30615,980USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-301,295,234shares
At 2025-12-31117,780shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2026-06-3012,167,136USD
At 2025-12-311,003,904USD
At 2025-06-30206,233USD
At 2024-12-313,633USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-06-3043,506,805USD
At 2025-12-3120,881,740USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2026-06-30714,088USD
At 2025-12-311,008,569USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2026-06-301,009,958USD
At 2025-12-3155,102USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-1,268,142USD91
2026-01-01 to 2026-06-30-4,491,034USD181
2025-04-01 to 2025-06-30-1,981,293USD91
2025-01-01 to 2025-06-30-17,922,621USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30970,211USD91
2026-01-01 to 2026-06-301,990,668USD181
2025-04-01 to 2025-06-30395,692USD91
2025-01-01 to 2025-06-3015,469,240USD181

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2026-01-01 to 2026-06-301,595,315USD181
2025-04-01 to 2025-06-30527,893USD91
2025-01-01 to 2025-06-30817,824USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,410,080USD91
2026-01-01 to 2026-06-30-166,643USD181
2025-04-01 to 2025-06-30-1,181,403USD91
2025-01-01 to 2025-06-30-1,566,251USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2026-01-01 to 2026-06-3017,951,119USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-06-3077,662USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-11,946USD181
2025-01-01 to 2025-06-301,041,420USD181

Inspect the source

Entity
ASPIRE BIOPHARMA HOLDINGS, INC. / CIK 0001847345
Captured
2026-09-21T17:32:16.061Z
SEC response SHA-256
40d6d0e6731934d6542812e865819d815a2e8f7284c4e26de8ab491caca2a549

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001847345.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))